The Effect of Neoadjuvant Chemotherapy on Cell Apoptosis and Proliferation in Stage m Non-small Cell Lung Cancer
-
摘要: 目的:探讨新辅助化疗对非小细胞肺癌肿瘤细胞凋亡及对肿瘤细胞增殖的影响。方法:选取Ⅲ期非小细胞肺癌患者56例行新辅助化疗后并手术,并选取同期50例直接手术患者作为对照组。两组患者的手术标本,分别采用末端转移酶介导的dUTP切口末端标记法(TUNEL)行细胞凋亡检测,采用免疫组化标记链菌亲和素生物素法(LSAB),检测细胞增殖抗原Ki-67的表达。结果:新辅助化疗组肿瘤细胞凋亡指数(AI)均数为9.34%,对照组肿瘤细胞凋亡指数均数为5.27%,两组比较有显著差异(P<0.001)。新辅助化疗组肿瘤细胞增殖抗原Ki-67阳性表达率均数为35.68%,对照组Ki-67阳性表达率均数为59.35%,两组比较差异显著(P<0.001)。新辅助化疗组及对照组中,肿瘤细胞凋亡指数AI与增殖指数Ki-67的阳性表达均成负相关。结论:新辅助化疗能诱导Ⅲ期非小细胞肺癌肿瘤细胞的凋亡,并能抑制其增殖。Abstract: Objective: To investigate whether neoadjuvant chemotherapy can induce tumor cell apoptosis in non- small cell lung cancer patients, and to study its effect on cell proliferation. Methods:Fifty- six patients with stage III non- small cell lung cancer were treated with neoadjuvant chemotherapy, and 50 with the same stage were directly treated with surgery as control. Apoptosis index (AI) of tumor cells was assayed by TdT- mediated dUTP nick end labeling (TUNEL) and Cell proliferation antigen (ki- 67) was examined using immunohistochemical labeled streptavidin biotin (LSAB) in the cancer samples. Results: Tumor cell AI in neoadjuvant group (X=9.34%) was significantly higher compared to control group (X=5.27%) (P<0.01). Ki- 67 positive expression rate in neoajuvant group (X=35.68%) was significantly lower than that in control group (X=59.35%) (P<0.01). There was a significant negative association between AI and Ki- 67 in both neoadjuvant chemotherapy group and control group (P<0.01).Conclutions: Neoadjuvant chemotherapy can induce tumor cell apoptosis and can inhibit the tumor cell proliferation in non- small cell lung cancer.
-
-
[1] 1 Mandziuk S,Dudzisz-Sledz M,Rybacka-Chabros B.Expression of p21 and bcl-2 proteins and p53 mRNA in surgically resected preparations of non-small cell lung cancer (stage ⅢA) after etoposide and cisplatin chemotherapy[J].Folia Histochemica et Cytobiologica,2001.175-176.
2 Junker K,Langner K,Klinke F.Grading of tumor regression in non-small cell lung cancer:morphology and prognosis[J].CHEST,2001,(5):1584-1591.
3 Rosell R,Felip E,Maestre J.The role of chemotherapy in early non-small-cell lung cancer management[J].Lung Cancer,2001,(Suppl 3):63-74.
4 彭忠民,陈景寒,王潍博.新辅助化疗加手术对Ⅲ期非小细胞肺癌患者预后的影响[J].中国肿瘤临床,2004,(15):864-866.
5 Langner K,Thomas M,Klinke F.Neoadjuvant therapy in non-small cell lung cancer.Prognostic impact of "mediastinal downstaging"[J].CHIRURG,2003.42-48.
6 Shiba M,Kohno H,Kakizawa K.Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma[J].Cancer,2000,(7):1457-1465.
7 MacDonald C,Michael A,Colston K.Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma[J].European Journal of Cancer,2004,(03):461-466.
8 Shivapurkar N,Reddy J,Chaudhary PM.Apoptosis and lung cancer:A review[J].Journal of Cellular Biochemistry,2003,(05):885-898.
9 Ellis PA,Smith IE,Detre S.Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy[J].Breast Cancer Research and Treatment,1998,(02):107-116.
10 Junker K,Muller KM,Bosse U.Apoptosis and tumor regression in locally advanced non-small cell lung cancer with neoadjuvant therapy[J].Pathologe,2003,(03):214-219.
计量
- 文章访问数: 1
- HTML全文浏览量: 0
- PDF下载量: 1
下载:
